Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. Jazz Pharmaceuticals plc has a strategic collaboration agreement with Codiak BioSciences, Inc. The company is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone353-1634-7800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.62 billion
Profitability
Miscellaneous
Employees1,210
OptionableOptionable
Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions
What is Jazz Pharmaceuticals' stock symbol?
Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
How were Jazz Pharmaceuticals' earnings last quarter?
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) released its quarterly earnings data on Tuesday, August, 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.23 by $0.26. The specialty pharmaceutical company earned $500.48 million during the quarter, compared to analysts' expectations of $469.85 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. View Jazz Pharmaceuticals' Earnings History.
When is Jazz Pharmaceuticals' next earnings date?
What price target have analysts set for JAZZ?
17 Wall Street analysts have issued 12-month target prices for Jazz Pharmaceuticals' stock. Their forecasts range from $157.00 to $210.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $189.4375 in the next year. This suggests a possible upside of 49.2% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals.
What is the consensus analysts' recommendation for Jazz Pharmaceuticals?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals.
What are Wall Street analysts saying about Jazz Pharmaceuticals stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Jazz Pharmaceuticals’ sleep disorder drug, Xyrem, has witnessed improved volume trends so far in 2018, sales were disappointing in 2017. Notably, Xyrem generates majority of sales, and consequently any setback is likely to hamper Jazz’s top-line. Moreover, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity. These supply challenges are expected to continue in 2019. Meanwhile, its newest drug Vyxeos performed below expectations leading Jazz to lower its full-year outlook. However, management seems confident that Xyrem will continue to generate volume growth in future quarters. The company’s lead pipeline candidate solriamfetol complements its existing sleep disorder portfolio. Estimates movement remianed mixed ahead of Q4 earnings. Jazz has a positive record of earnings surprises in the recent quarters." (2/14/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating on JAZZ stock and reducing our 12 month price target to $185, from $201. Our price target reduction of is driven by 1) Removal of Erwinaze post 2020; 2) Revision of Erwinaze sales in 2019 and 2020 to account for continued supply disruption, and a decreased focus on of revenue and spending assumptions ex- Erwinaze, largely within JAZZ’s hemo/oncology segment. Today’s announcement drives ~3% of our price target revision. We continue to believe JAZZ trades at a discount to its intrinsic value driven by overhangs on Xyrem generic entry, Vyxeos uptake, and Erwinaze uncertainty." (2/12/2019)
- 3. HC Wainwright analysts commented, "We highlighted after 1Q that management seemed to be taking a decidedly conservative approach to guidance this year, and this quarter we again see a healthy beat with little or no full-year raise. We still think guidance is a bit conservative (we’re near the high end on REV and EPS), but besides a small revenue drag from the sale of Prialt, unfortunately there was a key underperformer holding Jazz guidance back: Vyxeos. Jazz’s newest growth driver, from its most recent acquisition, only grew modestly QoQ, missed consensus for the second straight quarter, and Jazz lowered the product’s 2018 guidance 12% at the midpoint to $115-135M." (8/9/2018)
- 4. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018)
Has Jazz Pharmaceuticals been receiving favorable news coverage?
Headlines about JAZZ stock have been trending neutral this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Jazz Pharmaceuticals earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days.
Who are some of Jazz Pharmaceuticals' key competitors?
Some companies that are related to Jazz Pharmaceuticals include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS).
Who are Jazz Pharmaceuticals' key executives?
Jazz Pharmaceuticals' management team includes the folowing people:
- Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)
- Mr. Matthew P. Young, Exec. VP & CFO (Age 50)
- Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 53)
- Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)
- Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)
Who are Jazz Pharmaceuticals' major shareholders?
Jazz Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.86%), Bank of New York Mellon Corp (2.40%), Boston Partners (2.18%), Westfield Capital Management Co. LP (1.90%), LSV Asset Management (1.27%) and APG Asset Management N.V. (0.96%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.
Which major investors are selling Jazz Pharmaceuticals stock?
JAZZ stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Victory Capital Management Inc., Bank of America Corp DE, Polar Capital LLP, Monarch Partners Asset Management LLC, RK Capital Management LLC and Congress Asset Management Co. MA. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.
Which major investors are buying Jazz Pharmaceuticals stock?
JAZZ stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Scout Investments Inc., Boston Partners, Lord Abbett & CO. LLC, Dimensional Fund Advisors LP, APG Asset Management N.V., Amundi Pioneer Asset Management Inc. and Millennium Management LLC. View Insider Buying and Selling for Jazz Pharmaceuticals.
How do I buy shares of Jazz Pharmaceuticals?
Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jazz Pharmaceuticals' stock price today?
One share of JAZZ stock can currently be purchased for approximately $126.98.
How big of a company is Jazz Pharmaceuticals?
Jazz Pharmaceuticals has a market capitalization of $7.66 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.
What is Jazz Pharmaceuticals' official website?
How can I contact Jazz Pharmaceuticals?
Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]
MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
